Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

Award Number: R44CA189499
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/08/2014
PERIOD OF PERFORMANCE END DATE: 07/31/2019

Group Awards By:

View Award Description

Design of a Covalent Inhibitor for c-Myc-Dependent Cancers - DESCRIPTION (provided by applicant): The main commercial goal of our company is to develop novel therapeutics to inhibit the human oncogene, c-Myc. C-Myc is a major human oncogene that is estimated to contribute to at least 70% of all human cancers, most of which are aggressive and respond poorly to current therapies. Despite more than 30 years of research on c-Myc, the development of drugs that inhibit c-Myc has been unsuccessful because the protein is a transcription factor that lacks pockets for small molecules to bind. Therefore, developing novel treatments that inhibit c-Myc is considered one of the most important goals for advancing cancer therapeutics. Recently studies from several laboratories, including ours, have shown that the small ubiquitin-like modifications (SUMO) are critical for c-Myc- dependent tumorigenesis. Therefore, our research has focused on inhibiting c-Myc by targeting SUMOylation. Our initial studies are focused on colorectal cancers, because nearly 100% of these cancers depend on c-Myc, and new therapies are critically needed for metastatic colorectal cancers to improve patient survival. SUMOylation is important for c-Myc expression by activating ß- catenin/Tcf-4, the key transcription factor for inducing c-Myc expression in colorectal cancers. We have successfully completed the studies proposed for our Phase I SBIR award and have developed a new series of lead compounds that have improved potency and specificity. In Phase II studies, we propose to conduct necessary pharmacology formulation development, Chemistry, Manufacturing and Controls work, and IND-enabling studies. At the completion of these preclinical Phase II studies we anticipate being prepared to file an IND application to support further progress toward clinical trials. Ultimately, development of effective c-Myc-inhibiting drug would be paradigm-shifting for cancer treatment and fill a major void in the market.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2016	SUMO BIOSCIENCES INC.	2265 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Cancer Treatment Research	000	3	2/19/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	SUMO BIOSCIENCES INC.	2265 E FOOTHILL BLVD	PASADENA	CA	91107	LOS ANGELES	USA	Cancer Treatment Research	000	3	9/3/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $1,208,769 )
2016	2016	SUMO BIOSCIENCES LLC	94 ONTARE RD	ARCADIA	CA	91006	LOS ANGELES	USA	Cancer Treatment Research	000	3	7/18/2016	NON-COMPETING CONTINUATION	$1,208,769
														Subtotal = $1,208,769

Issue Date FY: 2015 ( Subtotal = $788,879 )
2015	2015	SUMO BIOSCIENCES LLC	94 ONTARE RD	ARCADIA	CA	91006	LOS ANGELES	USA	Cancer Treatment Research	000	2	8/4/2015	COMPETING CONTINUATION	$788,879
														Subtotal = $788,879

Grand Total All Awards = $1,997,648

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Design of a Covalent Inhibitor for c-Myc-Dependent Cancers

Award Number: R44CA189499

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/08/2014

PERIOD OF PERFORMANCE END DATE: 07/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer